Written Authority Required Drugs

Autosomal dominant polycystic kidney disease

The Pharmaceutical Benefits Scheme (PBS) subsidises tolvaptan for patients with autosomal dominant polycystic kidney disease (ADPKD).

Patient eligibility

The PBS subsidises treatment with tolvaptan under the National Health Act 1953, section 85 for patients with ADPKD.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing tolvaptan.

Treatment specifics

For initial PBS subsidised treatment, patients must be treated by a nephrologist.

For continuing PBS subsidised treatment, patients must be treated by or in consultation with a nephrologist.


Initial treatment

Apply for initial authority approval to prescribe PBS subsidised tolvaptan to treat ADPKD in writing and either:

All applications must include the completed:

Continuing treatment

Continuing PBS subsidised treatment with tolvaptan is Authority Required (Streamlined). It doesn’t need prior authority approval from us for listed quantities and repeats.

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

This information was printed Monday 20 May 2019 from https://www.humanservices.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/autosomal-dominant-polycystic-kidney-disease It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.humanservices.gov.au/individuals/site-notices when using this material.

Page last updated: 22 February 2019